T Cell therapy is one of the more exciting explorations of personalized immuno-oncology for blood cancers being undertaken today in the pharmaceutical industry. But, there may be some serious concerns around the marketability of the treatments, an analyst with research and data firm GlobalData told BioSpace (DHX).
CAR-T therapies are seen by many as a potent weapon in the fight against cancer. Chimeric antigen receptor T cells (CAR-T) are engineered to recognize and kill cancer. Steven Rosenberg, an oncology researcher at the Center for Cancer Research, wrote in a 2013 article in “Nature Reviews Clinical Oncology” that “CAR T-cell therapy eventually may become a standard therapy for some B-cell malignancies.”
However, in a new report, Cai Xuan, GlobalData’s analyst covering Oncology and Hematology, said T Cell therapies being developed by such companies as Novartis (NVS), Juno Therapeutics (JUNO), Kite Pharma (KITE) and more, are being hailed as potential breakthroughs in oncology treatments for blood cancers, but the per patient cost is so high, that it must “demonstrate curative ability before it can be considered as a frontline treatment.”
Xuan pegs the cost of potential T Cell treatments as ranging between $300,000 and $500,000 per patient, while existing treatment options, which include stem cell transplantation, have a price point of between $100,000 to $200,000. In addition to the high costs of T Cell therapies, Xuan noted there are also “long and difficult manufacturing” hurdles that must be overcome as well. Xuan said the CAR-T therapies are tailor-made for the individual patient, but that means there is a “complicated and expensive” manufacturing process involved.
Via Dominique Blanchard